DLDelphine Leclerc

Delphine Leclerc

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Delphine Leclerc has a total of 69 co-authors. Here are the top co-authors by number of shared publications:

  • A. Messager

    Université Bretagne Sud

    1 shared publication
  • Adeline Mallard

    Hôpital Louis Mourier - AP-HP [Colombes] (178 Rue des Renouillers, 92700 Colombes - France)

    1 shared publication
  • Albert Faye

    Department of General Paediatrics, Paediatric Internal Medicine, Rheumatology and Infectious Diseases, National Reference Centre for Rare Paediatric Inflammatory Rheumatisms and Systemic Autoimmune Diseases (RAISE), Robert-Debré University Hospital, Assistance Publique-Hôpitaux de Paris, F-75019, Paris, France

    1 shared publication
  • Anais M. Quemener

    University of Rennes, Centre National de la Recherche Scientifique (CNRS), Institut de Génétique et Développement de Rennes (IGDR) - UMR 6290, Rennes, France

    1 shared publication
  • Anna Gergely

    HUN-REN Hungarian Research Center for Natural Sciences, Institute of Cognitive Sciences and Psychology, Budapest, Hungary

    1 shared publication
  • Benjamin Wyplosz

    AP-HP, Hospitalisation à Domicile, Département Adulte, Institut Pasteur, Centre Médical, Paris, France

    1 shared publication

Latest Publications

  • Open Access

    A Single Lipid Nanoparticle Formulation Enables Delivery of Diverse RNA Therapeutics to Human Muscle Models of Duchenne Muscular Dystrophy

    by Paola Galbiati, Delphine Leclerc, Margaux Mombled, Ruqayya Khan, Maelle Ralu, Giorgia Bimbi, Giulia Scalisi, Kamel Mamchaoui, Francesco Saverio Tedesco, Sonia Albini, et al.

    Duchenne muscular dystrophy is a lethal neuromuscular disorder caused by the absence of dystrophin, for which no curative treatment is available. RNA based approaches have shown promising results; however, their evaluation is hindered by the lack of robust and rapid delivery methods for differentiated human muscle cells, which represent the most physiologically relevant in vitro models for assessing therapeutic strategies. Here, we establish a versatile lipid nanoparticle platform enabling efficient delivery of diverse RNA therapeutics across a range of human muscle models, including myotubes, induced pluripotent stem cell-derived myotubes, myoblasts, cardiomyocytes, and 3D engineered skeletal muscle tissues. Remarkably, a single commercially available lipid nanoparticle formulation supports delivery of cargos spanning more than 300-fold in size, from short antisense oligonucleotides (~20 nt) to complex CRISPR-based editors (up to ~6.7 kb), including Cas9 nucleases, adenine base editors, and CRISPRa systems. This enables efficient gene correction and transcriptional modulation, resulting in dystrophin restoration or compensatory utrophin upregulation in relevant Duchenne muscular dystrophy models. Together, our results establish a single lipid nanoparticle formulation as a versatile platform for RNA delivery in human muscle systems and provide a practical framework for the rapid preclinical assessment of emerging therapies for Duchenne muscular dystrophy and other neuromuscular disorders.

  • Évaluation des outils d’édition du génome pour les applications biomédicales : du diagnostic au traitement

    by Delphine Leclerc

    Ces dernières années, de considérables progrès ont été obtenus en médecine génomique. L’apport de la technologie de séquençage haut-débit dans les laboratoires de génétique médicale a notamment permis de mieux diagnostiquer les pathologies génétiques rares. Malgré cette avancée, un nombre important de patients diagnostiqués se retrouvent en errance thérapeutique. Environ 250 millions de personnes souffrent de pathologies génétiques rares et moins de 5% de ces pathologies disposent aujourd’hui de traitements efficaces. La découverte et l’amélioration constante des outils CRISPR/Cas9 ont ouvert la porte à une nouvelle médecine, la chirurgie du génome. Dans ce contexte, une partie importante des altérations génétiques responsables de maladies rares peuvent être en théorie directement corrigées par cette approche, ouvrant une perspective thérapeutique inespérée pour des patients étant parfois les seuls porteurs de ces altérations génétiques. Au cours de ma thèse, j’ai l’opportunité de développer et d’évaluer les outils d’édition du génome CRISPR/Cas9, d’une part pour concevoir et mesurer l’efficacité de nouveaux traitement in vitro, et d’autre part pour installer et décrypter le rôle biologique de variants génétiques de signification inconnue. Désormais, il est possible de corriger ou créer ces variants en recherche fondamentale afin d’aider les cliniciens à conclure sur leur rôle biologique ouvrant la porte à des thérapies personnalisées dans un futur proche.

  • Open Access

    TGFβ-induced circLTBP2 predicts a poor prognosis in intrahepatic cholangiocarcinoma and mediates gemcitabine resistance by sponging miR-338-3p

    by Corentin Louis, Tanguy Ferlier, Raffaële Leroux, Raphaël Pineau, Matthis Desoteux, Panagiotis Papoutsoglou, Delphine Leclerc, Gaëlle Angenard, Javier Vaquero, Rocio I.R. Macias, et al.


  • Open Access

    Uveal Melanoma: a miR-16 disease?

    by Anaïs M. Quéméner, Laura Bachelot, Marc Aubry, Stéphane Avner, Delphine Leclerc, Gilles Salbert, Florian Cabillic, Didier Decaudin, Bernard Mari, Frédéric Mouriaux, et al.

    Uveal melanoma (UM), the most common primary intraocular tumor in adults, has been extensively characterized by omics technologies during the last 5 years. Despite the discovery of gene signatures, the molecular actors driving the cancer aggressiveness are not fully understood and UM is still associated to a dismal overall survival at metastatic stage. Here, we showed that microRNA-16 (miR-16) is involved in uveal melanoma by an unexpected mechanism. By defining the miR-16-interactome, we revealed that miR-16 mainly interacts via non-canonical base-pairing to a subset of RNAs, promoting their expression levels (sponge RNAs). Consequently, the canonical miR-16 activity, involved in the RNA decay of oncogenes such as cyclin D1 and D3, is impaired. This miR-16 non-canonical base-pairing to sponge RNAs can explain both the derepression of miR-16 targets and the promotion of oncogenes expression observed for patients with poor overall survival in two cohorts. miR-16 activity assessment using our sponge-signature discriminates the patient’s overall survival as efficiently as the current method based on copy number variations and driver mutations detection. To conclude, miRNA loss of function due to miRNA sequestration seems to promote cancer burden by two combined events – “loss of brake and an acceleration”. Our results highlight the oncogenic role of the non-canonical base-pairing between miRNAs/mRNAs in uveal melanoma.

  • CHRONOVAC VOYAGEUR: A study of the immune response to yellow fever vaccine among infants previously immunized against measles

    by Catherine Goujon, Marie-Lise Gougeon, Laura Tondeur, Béatrice Poirier, Valérie Seffer, Philippe Desprès, Paul-Henri Consigny, Muriel Vray, Valentin Bandé, Ghania Benabdelmoumen, et al.


  • TROP-02 - Influence du genre sur l’observance de la prophylaxie antipalustre : étude multicentrique par auto questionnaires en ligne

    by M. Gousseff, A. Messager, N. Vignier, B. Issartel, F. Suy, M. Bloch, V. Delbos, S. Blanchi, D. Leclerc, P. Tattevin